Conflict of interest: none declared.
Elevated levels of plasma matrix metalloproteinase-9 in patients with atopic dermatitis: a pilot study
Article first published online: 5 MAR 2007
Clinical and Experimental Dermatology
Volume 32, Issue 3, pages 311–313, May 2007
How to Cite
Devillers, A. C. A., Van Toorenenbergen, A. W., Klein Heerenbrink, G. J., Mulder, P. G. H. and Oranje, A. P. (2007), Elevated levels of plasma matrix metalloproteinase-9 in patients with atopic dermatitis: a pilot study. Clinical and Experimental Dermatology, 32: 311–313. doi: 10.1111/j.1365-2230.2007.02378.x
- Issue published online: 5 MAR 2007
- Article first published online: 5 MAR 2007
- Accepted for publication 8 December 2006
Matrix metalloproteinase (MMP)-9 has been shown to play a role in the infiltration of inflammatory cells in various tissues. It is thus part of the pathogenesis of many inflammatory diseases, including asthma and allergic rhinitis/conjunctivitis. We compared plasma MMP-9 levels of 20 patients with atopic dermatitis (AD) with that of 17 control subjects. Additional outcome parameters consisted of the modified objective SCORing Atopic Dermatitis and the Three Item Severity score in patients, and peripheral blood leucocytes and eosinophils in both groups. Plasma MMP-9 levels were found to be significantly higher in patients compared with controls, supporting a role for MMP-9 in the pathogenesis of AD.